|
|
Vaccine Detail
|
Tripartite Branched Penetratin-Multiple Antigen Peptide (MAP)-MUC1 VNTR-Tetanus Toxoid Vaccine [AntpMAPMUC1tet] |
| Vaccine Information |
- Vaccine Name: Tripartite Branched Penetratin-Multiple Antigen Peptide (MAP)-MUC1 VNTR-Tetanus Toxoid Vaccine [AntpMAPMUC1tet]
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Peptide
- Status: Research
- Host Species for Licensed Use: Mouse
- Antigen: single MUC1 VNTR-derived 23-aa peptide (PGSTAPPAHGVTSAPDTRPAPGS) (Brooks et al., 2018)
- Immunization Route: Intradermal injection (i.d.)
- Description: A branched tripartite synthetic peptide vaccine (AntpMAPMUC1tet) incorporating penetratin (Antp; RQIKIWFQNRRMKWKKENK) as a cell-penetrating peptide for cytoplasmic antigen delivery, a single MUC1 variable number of tandem repeat (VNTR; PGSTAPPAHGVTSAPDTRPAPGS) containing both the H-2Kb-restricted CTL epitope (SAPDTRPAP) and HLA-A2-restricted CTL epitope (STAPPAHGV), and a universal tetanus toxoid CD4 T helper epitope (tetCD4; QYIKANSKFIGITEL). AntpMAPMUC1tet preferentially targets the mature CD8low DEC 205+ migratory DC subset in draining lymph nodes in vivo but does not induce DC maturation alone; CpG-ODN 1668 co-administration is essential for upregulation of CD40, CD80, CD86, and MHC class II. In C57BL/6 mice, AntpMAPMUC1tet + CpG-ODN 1668 (100 µg + 50 µg, i.d., days 0/10/17) induced enhanced MUC1-specific IFN-γ and IL-4 responses, a Th1-dominant IgG2a/IgG1 antibody profile, and greater in vivo CTL lysis (80% vs 55%, p<0.05). In a prophylactic B16-MUC1 melanoma challenge, AntpMAPMUC1tet + CpG-ODN 1668 significantly delayed tumor growth (28.6 ± 9.1 mm² vs 61.5–66.0 mm² at day 28, p<0.05), with 2/8 mice tumor-free and prolonged survival (38.5 vs 32 vs 29.5 days, p=0.006). Long-term memory responses at 40 days post-immunization showed sustained CTL lysis (65% vs 41%, p<0.001) and durable IgG2a-predominant antibody titers (Brooks et al., 2018).
|
| Host Response |
|
|
| References |
Brooks et al., 2018: Brooks N, Hsu J, Esparon S, Pouniotis D, Pietersz GA. Immunogenicity of a Tripartite Cell Penetrating Peptide Containing a MUC1 Variable Number of Tandem Repeat (VNTR) and A T Helper Epitope. Molecules (Basel, Switzerland). 2018; 23(9); . [PubMed: 30200528].
|
|
